First-pass disposition of (-)-6-aminocarbovlr in rats. I. Prodrug activation may be limited by access to enzyme

Yandong Wen, Rory P. Remmel, Cheryl L. Zimmerman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean ± S.D.) in the cytosolic fractions obtained from homogenates of the intestine, liver, and intestinal contents were 0.4 ± 0.1 (n = 3), 12.2 ± 1.1 (n = 3), and 15.5 (n = 1) min, respectively. An in situ vascularly perfused intestine-liver (IPIL) study was then carried out (n = 6) to determine the relative contribution of each presystemic organ to the overall first-pass extraction of 6AC. The 6AC extraction ratios in the intestine and liver in the IPIL were found to be 0.08 ± 0.02 and 0.11 ± 0.03, respectively. The intestinal extraction ratio was in dramatic contrast to the in vitro results. It was postulated that vascularly delivered 6AC had limited access to the metabolic site in the intestine. A theoretical analysis suggested that the extent of intestinal wall extraction of 6AC would be underestimated by the IPIL and should be determined after oral dosing. To compare intestinal extraction ratio in the IPIL with that after an oral administration, in situ intestinal lumen perfusions (n = 4) and intraportal infusions (n = 3) of 6AC were conducted in two groups of rats. The lumenally administered 6AC was extracted to a much greater extent by the intestine as compared with the IPIL, which presents 6AC to the intestine by the vascular route. The extraction ratio was found to be 0.54 ± 0.06, which was significantly larger than that obtained in the IPIL.

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalDrug Metabolism and Disposition
Volume27
Issue number1
StatePublished - Jan 1 1999

Fingerprint

Prodrugs
Intestines
Rats
Chemical activation
Enzymes
Liver
Gastrointestinal Contents
Blood Vessels
Oral Administration
Perfusion
In Vitro Techniques

Cite this

First-pass disposition of (-)-6-aminocarbovlr in rats. I. Prodrug activation may be limited by access to enzyme. / Wen, Yandong; Remmel, Rory P.; Zimmerman, Cheryl L.

In: Drug Metabolism and Disposition, Vol. 27, No. 1, 01.01.1999, p. 113-121.

Research output: Contribution to journalArticle

@article{d81ecd8f829341a59af342c843c6551b,
title = "First-pass disposition of (-)-6-aminocarbovlr in rats. I. Prodrug activation may be limited by access to enzyme",
abstract = "Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean ± S.D.) in the cytosolic fractions obtained from homogenates of the intestine, liver, and intestinal contents were 0.4 ± 0.1 (n = 3), 12.2 ± 1.1 (n = 3), and 15.5 (n = 1) min, respectively. An in situ vascularly perfused intestine-liver (IPIL) study was then carried out (n = 6) to determine the relative contribution of each presystemic organ to the overall first-pass extraction of 6AC. The 6AC extraction ratios in the intestine and liver in the IPIL were found to be 0.08 ± 0.02 and 0.11 ± 0.03, respectively. The intestinal extraction ratio was in dramatic contrast to the in vitro results. It was postulated that vascularly delivered 6AC had limited access to the metabolic site in the intestine. A theoretical analysis suggested that the extent of intestinal wall extraction of 6AC would be underestimated by the IPIL and should be determined after oral dosing. To compare intestinal extraction ratio in the IPIL with that after an oral administration, in situ intestinal lumen perfusions (n = 4) and intraportal infusions (n = 3) of 6AC were conducted in two groups of rats. The lumenally administered 6AC was extracted to a much greater extent by the intestine as compared with the IPIL, which presents 6AC to the intestine by the vascular route. The extraction ratio was found to be 0.54 ± 0.06, which was significantly larger than that obtained in the IPIL.",
author = "Yandong Wen and Remmel, {Rory P.} and Zimmerman, {Cheryl L.}",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "27",
pages = "113--121",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - First-pass disposition of (-)-6-aminocarbovlr in rats. I. Prodrug activation may be limited by access to enzyme

AU - Wen, Yandong

AU - Remmel, Rory P.

AU - Zimmerman, Cheryl L.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean ± S.D.) in the cytosolic fractions obtained from homogenates of the intestine, liver, and intestinal contents were 0.4 ± 0.1 (n = 3), 12.2 ± 1.1 (n = 3), and 15.5 (n = 1) min, respectively. An in situ vascularly perfused intestine-liver (IPIL) study was then carried out (n = 6) to determine the relative contribution of each presystemic organ to the overall first-pass extraction of 6AC. The 6AC extraction ratios in the intestine and liver in the IPIL were found to be 0.08 ± 0.02 and 0.11 ± 0.03, respectively. The intestinal extraction ratio was in dramatic contrast to the in vitro results. It was postulated that vascularly delivered 6AC had limited access to the metabolic site in the intestine. A theoretical analysis suggested that the extent of intestinal wall extraction of 6AC would be underestimated by the IPIL and should be determined after oral dosing. To compare intestinal extraction ratio in the IPIL with that after an oral administration, in situ intestinal lumen perfusions (n = 4) and intraportal infusions (n = 3) of 6AC were conducted in two groups of rats. The lumenally administered 6AC was extracted to a much greater extent by the intestine as compared with the IPIL, which presents 6AC to the intestine by the vascular route. The extraction ratio was found to be 0.54 ± 0.06, which was significantly larger than that obtained in the IPIL.

AB - Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean ± S.D.) in the cytosolic fractions obtained from homogenates of the intestine, liver, and intestinal contents were 0.4 ± 0.1 (n = 3), 12.2 ± 1.1 (n = 3), and 15.5 (n = 1) min, respectively. An in situ vascularly perfused intestine-liver (IPIL) study was then carried out (n = 6) to determine the relative contribution of each presystemic organ to the overall first-pass extraction of 6AC. The 6AC extraction ratios in the intestine and liver in the IPIL were found to be 0.08 ± 0.02 and 0.11 ± 0.03, respectively. The intestinal extraction ratio was in dramatic contrast to the in vitro results. It was postulated that vascularly delivered 6AC had limited access to the metabolic site in the intestine. A theoretical analysis suggested that the extent of intestinal wall extraction of 6AC would be underestimated by the IPIL and should be determined after oral dosing. To compare intestinal extraction ratio in the IPIL with that after an oral administration, in situ intestinal lumen perfusions (n = 4) and intraportal infusions (n = 3) of 6AC were conducted in two groups of rats. The lumenally administered 6AC was extracted to a much greater extent by the intestine as compared with the IPIL, which presents 6AC to the intestine by the vascular route. The extraction ratio was found to be 0.54 ± 0.06, which was significantly larger than that obtained in the IPIL.

UR - http://www.scopus.com/inward/record.url?scp=0032969265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032969265&partnerID=8YFLogxK

M3 - Article

C2 - 9884319

AN - SCOPUS:0032969265

VL - 27

SP - 113

EP - 121

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -